Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Nonspecific reaction, Off label use, Pallor, Speech disorder
Clinical narrative: REVACCINATION WITH DIFFERENT COVID-19 VACCINE; VERY MILD REACTION; VERY MILD REACTION; OFF LABEL DOSING FREQUENCY; WEAK; DIZZY; UNABLE TO STAND UP / HAVING A DIFFICULT TIME STANDING; BACK WAS ALL SWEATY; PALE; HARDLY ABLE TO TALK; This spontaneous report received from a consumer via other manufacturer (Pfizer) concerned a male of unspecified age, race and ethnicity. The patient previously received first dose of covid-19 vaccine ad26.cov2.s (dose number in series 1) (suspension for injection, route of admin, and batch number were not reported) dose, start therapy dates were not reported, 1 total for covid-19 prophylaxis.  On an unspecified date, the patient experienced very mild reaction when treated first dose of covid-19 vaccine ad26. cov2. s (dose number in series 1).  The patient previously received booster dose of covid-19 vaccine ad26.cov2.s (dose number in series 2) (suspension for injection, route of admin, and batch number were not reported) dose, start therapy dates were not reported, 1 total for covid-19 prophylaxis.  On an unspecified date, the patient experienced very mild reaction when treated booster dose of covid-19 vaccine ad26. cov2. s (dose number in series 2).  The patient received third dose of covid-19 vaccine ad26.cov2.s (dose number in series 3) (suspension for injection, route of admin, and batch number were not reported) dose, start therapy dates were not reported, 1 total for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. The drug was associated with Off label use. On an unspecified date, the patient experienced very mild reaction and Off label use (dose number in series 3).  The patient received additional dose of non-company suspect vaccine included: (Moderna covid-19 vaccine) (elasomeran) (dose number in series 4) (form of admin, route of admin, and batch number were not reported), dose, start therapy date were not reported for covid-19 prophylaxis. The patient experienced revaccination with different covid-19 vaccine and very mild reaction when treated with Moderna covid-19 vaccine (elasomeran) (dose number in series 4). The patient received fifth dose of non-company suspect vaccine included: (Pfizer covid-19 vaccine) (tozinameran) (dose number in series 5) (form of admin, route of admin were not reported and batch number; PF12) dose was not reported, administered on 12-SEP-2022 for covid-19 prophylaxis. No concomitant medications were reported. On an unspecified date in SEP-2022, after receiving the vaccine the patient experienced very intense reaction, he was unable to stand up, his back was all sweaty, he was pale and weak. Patient was hardly able to talk and was dizzy. He was having a difficult time standing (dose number in series 5). It was reported that, the patient had two regular Johnson and Johnson, one booster Johnson and Johnson and one booster Moderna and then a day prior to this report the patient had received Pfizer booster. It was also reported that the patient had very mild reaction to Johnson and Johnson and Moderna but he had a very intense reaction to the Pfizer, he was unable to stand up, his back was all sweaty, he was pale, and weak. He was hardly able to talk and was dizzy and he was having a difficult time standing. He is feeling a little better now (at time of this report). The action taken with covid-19 vaccine ad26.cov2.s, elasomeran, and tozinameran was not applicable. The patient was recovering from unable to stand up / having a difficult time standing, back was all sweaty, pale, weak, hardly able to talk, and dizzy, and the outcome of revaccination with different covid-19 vaccine, off label dosing frequency and very mild reaction was not reported. This report was non-serious. This case, involving the same patient is linked .